A dysfunctional miR-1-TRPS1-MYOG axis drives ERMS by suppressing terminal myogenic differentiation

Area of Science:

• Oncology
• Molecular Biology
• Developmental Biology

Background:

• Rhabdomyosarcoma is a common pediatric soft tissue tumor with two main subtypes: embryonal (PAX3/7-FOXO1 fusion-negative) and alveolar (PAX3/7-FOXO1 fusion-positive).
• TRPS1, a transcriptional repressor, plays a role in normal muscle development by regulating gene expression during myogenesis.

Purpose of the Study:

• To investigate the role of TRPS1 expression in embryonal rhabdomyosarcoma (eRMS) pathogenesis.
• To explore the therapeutic potential of targeting TRPS1 for eRMS treatment.

Main Methods:

• Analysis of TRPS1 expression levels in eRMS subtypes.
• In vitro and in vivo studies involving TRPS1 manipulation in rhabdomyosarcoma cells.
• Investigation of TRPS1 regulation by microRNA-1 (miR-1) and its interaction with MYOD1.
• Assessment of TRPS1's effect on myogenin (MYOG) promoter activity.

Main Results:

• TRPS1 expression is significantly elevated in the embryonal subtype of rhabdomyosarcoma.
• Overexpression of TRPS1 inhibits terminal myogenic differentiation, while its reduction promotes differentiation in eRMS cells.
• TRPS1 levels are regulated by miR-1, and TRPS1 shares genomic binding sites with MYOD1, a key muscle regulatory factor.
• TRPS1 directly represses MYOG expression, a critical step in myogenic differentiation.

Conclusions:

• Elevated TRPS1 expression impairs myogenic differentiation in embryonal rhabdomyosarcoma.
• Reducing TRPS1 levels offers a potential therapeutic strategy to induce terminal myogenic differentiation in eRMS.
• Targeting TRPS1 could lead to the generation of postmitotic myotubes, offering a novel treatment approach for eRMS.